Global Information
회사소개 | 문의 | 비교리스트

의료기기 리더 시리즈 : 체외진단(IVD) 분야의 유력 기업(2019-2029년)

Medical Devices Leader Series - Top In Vitro Diagnostics (IVD) Companies 2019-2029: Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Roche, Siemens AG, Sysmex, Other Companies

리서치사 Visiongain Ltd
발행일 2019년 05월 상품 코드 264338
페이지 정보 영문 204 Pages
가격
£ 3,499 ₩ 5,530,000 Unprintable PDF (Single User) - 1 Year License help
1명만 이용할 수 있는 라이센스입니다. DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 인증된 PC 1대에서만 열람이 가능하며, 구입일로부터 1년간 유효합니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄 또한 불가능합니다.
£ 3,899 ₩ 6,162,000 PDF (Departmental - 5 Users) - 1 Year License help
동일 사업장(소재지) 내 5명까지 이용할 수 있는 라이센스입니다. DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 인증된 PC에서만 열람이 가능하며, 구입일로부터 1년간 유효합니다. PDF파일은 Copy & Paste가 되지 않으며, 인쇄는 1명당 1회에 한해 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
£ 4,999 ₩ 7,901,000 PDF (Site License) help
동일 사업장(소재지) 내 모든 분이 이용할 수 있는 라이센스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 되지 않습니다. DRM(디지털 저작권 관리시스템)은 적용되어 있지 않지만, PDF 인쇄는 1명당 1회에 한해 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
£ 6,999 ₩ 11,062,000 PDF (Global License - Includes Free Datasets)

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



의료기기 리더 시리즈 : 체외진단(IVD) 분야의 유력 기업(2019-2029년) Medical Devices Leader Series - Top In Vitro Diagnostics (IVD) Companies 2019-2029: Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Roche, Siemens AG, Sysmex, Other Companies
발행일 : 2019년 05월 페이지 정보 : 영문 204 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 체외진단(IVD) 시장의 대표적 기업에 대해 분석했으며, 각 기업의 최근 실적 동향과 향후 전망, 주력 제품/서비스, 각 기업의 경쟁 우위/열위 분야, 최근의 사업 추진 상황(M&A 등) 등을 조사했으며, 업계 전체의 구조와 동향 전망, 주요 시장 성장 촉진·억제요인 등의 정보를 정리하여 전해드립니다.

제1장 보고서 개요

제2장 체외진단(IVD)의 서론

  • IVD 시장 : 최신 상황
  • IVD 검사란?
  • IVD의 분류
    • 미국의 분류
    • 유럽(EC)의 분류
    • IVD 시장의 규제상 문제
  • IVD 검사의 종류
    • Point of Care(POC) 진단
    • 임상화학 검사
    • 미생물 검사
    • 혈액 검사
    • 면역화학 검사
    • 유전자 검사
  • 체외진단 시장 전체의 매출 예측
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • IVD 산업의 미래
  • 기업 비교
    • 세분화된 시장
    • IVD 시장의 주요 기업

제3장 미국의 대표적인 체외진단(IVD) 기업

  • Danaher Corporation
    • 매출 및 최근의 실적 분석
    • 주요 제품 및 서비스
    • 연구개발(R&D)/생산능력
    • 시장 매출 예측(향후 11년간)
    • 최근의 기업 인수합병(M&A)/사업 추진 상황 등
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Becton, Dickinson and Company
  • Thermo Fisher Scientific

제4장 유럽의 대표적인 체외진단(IVD) 기업

  • Hoffmann-La Roche Ltd.
  • Siemens AG
  • bioMerieux S.A.

제5장 일본의 대표적인 체외진단(IVD) 기업

  • Sysmex Corporation
  • Arkray, Inc.

제6장 체외진단(IVD) 분야의 신흥 기업

  • 파이프라인 및 기타 기업 개요
  • 기타 유망한 IVD 기업
  • Dako(Agilent Technologies)
  • Genomic Health, Inc.
  • Laboratory Corporation of America(LabCorp)
  • MDxHealth, Inc.
  • Myriad Genetics, Inc.
    • Myriad RBM
  • QIAGEN N.V.

제7장 기타 IVD 기업

  • Hologic, Inc.
  • Bayer AG
  • Transasia Bio-Medicals Ltd.
  • PerkinElmer, Inc.
  • DiaSorin S.p.A.
  • Koninklijke Philips N.V.
  • Illumina, Inc.
  • Kem-en-tec Diagnostics A/S

제8장 결론

KSM 19.07.18

List of Tables

  • Table 2.1 IVD Revenues ($bn) and Market Shares (%) by Class, 2017-2018
  • Table 2.2 Advantages and Disadvantages of POC Diagnostics
  • Table 2.3 IVD Tests: Overall World Market and Submarket Revenue Forecasts ($bn), 2018, 2019, 2024 & 2029
  • Table 2.4 Leading Manufacturers: IVD Market Share (%), 2018
  • Table 2.5 Leading Companies in the IVD Market: Net Sales ($bn) and Market Shares (%), 2018
  • Table 3.1 Danaher: Key Facts
  • Table 3.2 Danaher: Net Sales ($bn) and Revenue Shares (%) by Business Segment, 2017
  • Table 3.3 Danaher: Life Sciences & Diagnostics Revenue ($bn), AGR (%), 2015-2017
  • Table 3.4 Danaher: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 3.5 Abbott: Key Facts
  • Table 3.6 Abbott: Net Sales ($bn) and Revenue Shares (%) by Business Segment, 2017
  • Table 3.7 Abbott: Revenues ($bn) and Revenue Shares (%) by Geographical Region, 2017
  • Table 3.8 Abbott: Diagnostics Revenue ($bn), AGR (%), 2015-2017
  • Table 3.9 Abbott: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 3.10 Bio-Rad: Key Facts
  • Table 3.11 Bio-Rad: Clinical Diagnostics Revenue ($bn), AGR (%) 2015-2017
  • Table 3.12 Bio-Rad: IVD Revenue Forecast ($bn), Growth (%), CAGR (%), Market Share (%) 2019-2029
  • Table 3.13 BD: Key Facts
  • Table 3.14 Becton Dickinson: Net Sales ($bn) and Revenue Shares (%) by Sector, 2017
  • Table 3.15 BD: Diagnostics Revenue ($bn), AGR (%) 2015-2017
  • Table 3.16 BD: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 3.17 Thermo Fisher: Key Facts
  • Table 3.18 Thermo Fisher: IVD Sales ($bn), AGR (%), 2015-2017
  • Table 3.19 Thermo Fisher: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 4.1 Roche: Key Facts
  • Table 4.2 Roche: Revenue ($bn) and Revenue Shares (%) by Sector, 2017
  • Table 4.3 Roche Diagnostics: Revenue ($bn) and Revenue Shares (%) by Sector, 2017
  • Table 4.4 Roche Diagnostics: Marketed Diagnostic Products
  • Table 4.5 Roche: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 4.6 Siemens: Key Facts
  • Table 4.7 Siemens: Revenue ($bn) and Revenue Shares (%) by Sector, 2017
  • Table 4.8 Siemens: Revenue ($bn) and Revenue Shares (%) by Region, 2017
  • Table 4.9 Siemens: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 4.10 bioMérieux: Key Facts
  • Table 4.11 bioMérieux: Revenue ($bn) and Revenue Shares (%) by Sector, 2017
  • Table 4.12 bioMérieux: Clinical Applications Revenue ($bn) and Revenue Shares (%) by Sector, 2017
  • Table 4.13 bioMérieux: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 5.1 Sysmex: Key Facts
  • Table 5.2 Sysmex: Revenue ($bn) by Sector, 2017
  • Table 5.3 Sysmex: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 5.4 Arkray: Key Facts
  • Table 5.5 Arkray: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 6.1 Agilent: Revenue ($bn) and Revenue Shares (%) by Sector, 2017
  • Table 6.2 Dako: Marketed Diagnostic Products, 2017
  • Table 6.3 Genomic Health: Revenue ($m) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 6.4 Genomic Health: R&D Expense ($m) and R&D Expense as a Percentage of Sales (%), 2013-2017
  • Table 6.5 LabCorp: Revenues ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 6.6 Selected List of LabCorp's Menu of Diagnostic Products, 2017
  • Table 6.7 MDxHealth: Revenue ($m) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 6.8 MDxHealth: In Vitro Diagnostics Pipeline, 2017
  • Table 6.9 Myriad: Revenue ($m) and Revenue Shares (%) by Sector, 2017
  • Table 6.10 Myriad Molecular Diagnostics: Revenue ($m) and Revenue Shares (%) by Product, 2017
  • Table 6.11 Myriad Molecular Diagnostics: Revenue ($m) and Revenue Shares (%) by Sector, 2017
  • Table 6.12 Myriad: Biomarker Product Portfolio, 2017
  • Table 6.13 Myriad: Diagnostic Products, 2017
  • Table 6.14 QIAGEN: Revenue ($m) and Revenue Shares (%) by Customer Class, 2017
  • Table 6.15 QIAGEN: Revenue ($m) and Revenue Shares (%) by Region, 2017
  • Table 6.16 QIAGEN: Selected List of Co-development Projects
  • Table 6.17 QIAGEN: Selected Marketed Diagnostic Products
  • Table 6.18 QIAGEN: Recent M&A Activity
  • Table 6.19 Other Companies Operating in the IVD Market, 2018
  • Table 7.1 Hologic, Inc.: Key Facts
  • Table 7.2 Hologic, Inc.: Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 7.3 Hologic, Inc.: Product Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 7.4 Hologic, Inc.: Clinical Diagnostics Revenue ($bn), AGR (%) 2015-2017
  • Table 7.5 Bayer AG: Key Facts, 2017
  • Table 7.6 Bayer AG: Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 7.7 Transasia Bio-Medicals Ltd: Key Facts, 2017
  • Table 7.8 PerkinElmer, Inc.: Key Facts, 2017
  • Table 7.9 PerkinElmer, Inc.: Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 7.10 PerkinElmer, Inc.: Product Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 7.11 PerkinElmer, Inc.: Clinical Diagnostics Revenue ($bn), AGR (%) 2015-2017
  • Table 7.12 DiaSorin: Key Facts, 2017
  • Table 7.13 DiaSorin: Revenue ($m) and Revenue Shares (%) by Geography, 2017
  • Table 7.14 Koninklijke Philips N.V.: Key Facts, 2017
  • Table 7.15 Koninklijke Philips N.V.: Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 7.16 Koninklijke Philips N.V.: Diagnosis & Treatment Revenue ($bn), AGR (%) 2015-2017
  • Table 7.17 Koninklijke Philips N.V.: Diagnosis & Treatment Product Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 7.18 Illumina, Inc.: Key Facts
  • Table 7.19 Illumina, Inc.: Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 7.20 Kem-en-tec Diagnostics A/S: Key Facts
  • Table 8.1 Leading IVD Manufacturers by Company Type, 2018

List of Figures

  • Figure 2.1 IVD Market ($bn) by Class 2018
  • Figure 2.2 IVD: Overall Market ($bn) Forecast, 2018, 2019, 2024 & 2029
  • Figure 2.3 IVD Market: Drivers and Restraints, 2019-2029
  • Figure 2.4 Leading Companies in the IVD Market: Net Sales ($bn), 2018
  • Figure 2.5 Leading Companies in the IVD Market: (% Share), 2018
  • Figure 3.1 Danaher: Net Sales ($bn) by Business Segment, 2017
  • Figure 3.2 Danaher: Revenue Shares (%) by Business Segment, 2017
  • Figure 3.3 Danaher: IVD Revenue ($bn) Forecast, AGR (%), 2019-2029
  • Figure 3.4 Danaher: IVD Market Share (%), 2019-2029
  • Figure 3.5 Abbott: Net Sales ($bn) by Business Segment, 2017
  • Figure 3.6 Abbott: Revenue Shares (%) by Business Segment, 2017
  • Figure 3.7 Abbott: Revenues ($bn) by Region, 2017
  • Figure 3.8 Abbott: Revenue Shares (%) by Region, 2017
  • Figure 3.9 Abbott: IVD Revenue ($bn) Forecast, AGR (%), 2019-2029
  • Figure 3.10 Abbott: IVD Market Share (%), 2019-2029
  • Figure 3.11 Bio-Rad: Historical Diagnostics Revenues ($bn) 2014-2017
  • Figure 3.12 Bio-Rad: Revenue Shares (%) by Business Segment, 2017
  • Figure 3.13 Bio-Rad: Revenue Shares (%) by Region, 2017
  • Figure 3.14 Bio-Rad: IVD Revenue Forecast ($bn), AGR (%), 2019-2029
  • Figure 3.15 Bio-Rad: IVD Market Share (%), 2019-2029
  • Figure 3.16 Becton Dickinson: Revenue Shares (%) by Sector, 2017
  • Figure 3.17 BD: Company Revenue ($bn), 2015-2017
  • Figure 3.18 BD IVD Revenue Forecast ($bn), AGR (%), 2019-2029
  • Figure 3.19 BD: IVD Market Share (%), 2019-2029
  • Figure 3.20 Thermo Fisher: IVD Net Sales ($bn), 2015-2017
  • Figure 3.21 Thermo Fisher: Revenue Shares (%) by Sector, 2017
  • Figure 3.22 Thermo Fisher: IVD Revenue ($bn) Forecast, AGR (%), 2019-2029
  • Figure 3.23 Thermo Fisher: IVD Market Share (%), 2019-2029
  • Figure 3.24 Thermo Fisher: Mergers & Acquisitions
  • Figure 4.1 Roche: Revenues ($bn) by Sector, 2017
  • Figure 4.2 Roche: Revenue Shares (%) by Sector, 2017
  • Figure 4.3 Roche Diagnostics: Revenues ($bn) by Sector, 2017
  • Figure 4.4 Roche Diagnostics: Revenue Shares (%) by Sector, 2017
  • Figure 4.5 Roche: IVD Revenue ($bn), AGR (%), Forecast, 2019-2029
  • Figure 4.6 Roche: IVD Market Share (%), 2019-2029
  • Figure 4.7 Siemens: Revenue Shares (%) by Sector, 2017
  • Figure 4.8 Siemens Healthcare: Revenue Shares (%) by Region, 2017
  • Figure 4.9 Siemens: IVD Revenue ($bn), AGR (%), Forecast 2019-2029
  • Figure 4.10 Siemens: IVD Market Share (%), 2019-2029
  • Figure 4.11 bioMérieux: Revenue ($bn) by Sector, 2017
  • Figure 4.12 bioMérieux: Revenue Shares (%) by Sector, 2017
  • Figure 4.13 bioMérieux: Clinical Applications Revenue ($bn) by Sector, 2017
  • Figure 4.14 bioMérieux: Clinical Applications Revenue Shares (%) by Sector, 2017
  • Figure 4.15 bioMérieux: IVD Revenue ($bn), AGR (%), Forecast, 2019-2029
  • Figure 4.16 bioMérieux: IVD Market Share (%), 2019-2029
  • Figure 5.1 Sysmex: Revenues ($bn) by Sector, 2017
  • Figure 5.2 Sysmex: Revenue Shares (%) by Sector, 2017
  • Figure 5.3 Sysmex: Net Sales (%) by Geographical Region, 2017
  • Figure 5.4 Sysmex: IVD Revenue ($bn) Forecast, AGR (%), 2019-2029
  • Figure 5.5 Sysmex: IVD Market Share (%), 2019-2029
  • Figure 5.6 Arkray: IVD Revenue ($bn) Forecast, (AGR %), 2019-2029
  • Figure 5.7 Arkray: IVD Market Share (%), 2019-2029
  • Figure 6.1 Agilent: Revenue ($bn) by Sector, 2017
  • Figure 6.2 Dako: Revenue Shares (%) by Sector, 2017
  • Figure 6.3 Genomic Health: Historical Revenues ($m) and Net Income ($m), 2013-2017
  • Figure 6.4 Genomic Health: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 6.5 Genomic Health: Historical R&D Expense ($m) and R&D as a Percentage of Net Sales (%), 2013-2017
  • Figure 6.6 LabCorp: Historical Revenue ($bn), Profit ($bn), 2013-2017
  • Figure 6.7 LabCorp: Revenues ($bn) by Reporting Segment, 2017
  • Figure 6.8 LabCorp: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 6.9 MDxHealth: Revenues ($m) by Reporting Segment, 2017
  • Figure 6.10 MDxHealth: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 6.11 Myriad: Historical Net Revenues ($m), 2013-2017
  • Figure 6.12 Myriad: Revenue Shares (%) by Sector, 2017
  • Figure 6.13 Myriad Molecular Diagnostics: Revenue Shares (%) by Product, 2017
  • Figure 6.14 Myriad Molecular Diagnostics: Revenue Shares (%) by Sector, 2017
  • Figure 6.15 Myriad: Historical R&D Investments ($m), 2013-2017
  • Figure 6.16 QIAGEN: Historical Revenue ($bn), Net Income ($bn), 2013-2017
  • Figure 6.17 QIAGEN: Revenues ($m) by Customer Class, 2017
  • Figure 6.18 QIAGEN: Revenue Shares (%) by Customer Class, 2017
  • Figure 6.19 QIAGEN: Revenue Shares (%) by Region, 2017
  • Figure 6.20 QIAGEN: Historical R&D Expense ($m) and R&D Expense as a Percentage of Net Revenue (%), 2013-2017
  • Figure 7.1 Hologic, Inc.: Historical Revenues ($bn) and Net Income ($bn), 2013-2017
  • Figure 7.2 Hologic, Inc.: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 7.3 Hologic, Inc.: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 7.4 Hologic, Inc.: Revenue Shares (%) by Region, 2017
  • Figure 7.5 Hologic, Inc.: Diagnostics Revenue Shares (%), 2017
  • Figure 7.6 Bayer AG: Historical Revenues ($bn) and Net Income ($bn), 2013-2017
  • Figure 7.7 Bayer AG: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 7.8 Bayer AG: Revenue Shares (%) by Region, 2017
  • Figure 7.9 PerkinElmer, Inc.: Historical Revenues ($bn), 2013-2017
  • Figure 7.10 PerkinElmer, Inc.: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 7.11 PerkinElmer, Inc.: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 7.12 PerkinElmer, Inc.: Revenue Shares (%) by Region, 2017
  • Figure 7.13 PerkinElmer, Inc.: Diagnostics Revenue Shares (%), 2017
  • Figure 7.14 DiaSorin: Historical Revenues ($m), 2013-2017
  • Figure 7.15 DiaSorin: Revenue Shares (%) by Region, 2017
  • Figure 7.16 Koninklijke Philips N.V.: Historical Revenues ($bn), 2013-2017
  • Figure 7.17 Koninklijke Philips N.V.: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 7.18 Koninklijke Philips N.V.: Revenue Shares (%) by Region, 2017
  • Figure 7.19 Koninklijke Philips N.V.: Diagnosis & Treatment Revenue ($b), 2017
  • Figure 7.20 Koninklijke Philips N.V.: Diagnosis & Treatment Revenue ($bn) by Product, 2017
  • Figure 7.21 Koninklijke Philips N.V.: Diagnosis & Treatment Revenue Shares (%) by Product, 2017
  • Figure 7.22 Illumina, Inc.: Historical Revenues ($bn) and Net Income ($bn), 2013-2017
  • Figure 7.23 Illumina, Inc.: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 7.24 Illumina, Inc.: Revenue Shares (%) by Region, 2017
  • Figure 8.1 IVD Market: Overall World Revenue ($bn), (AGR%) 2019-2029
  • Figure 8.2 IVD Market: Revenue ($bn) Forecasts, 2018, 2019, 2024, and 2029

COMPANIES LISTED:

  • AB SCIEX
  • Abbott Laboratories
  • AbD Serotec
  • Agilent Technologies
  • Alacris Theranostics GmbH
  • Alere
  • Amoy Diagnostics Co. Ltd
  • Analytical Informatics, Inc.
  • Arca biopharma
  • ARGENE
  • Arkray, Inc.
  • Astute Medical
  • Bayer
  • Beckman Coulter
  • Becton Dickinson
  • BioFire Diagnostics, LLC
  • BioMarin Pharmaceutical Inc.
  • bioMérieux
  • Bio-Rad Laboratories
  • Bristol-Myers Squibb
  • C. R. Bard, Inc.
  • Calbiotech Group of Companies
  • CareFusion
  • Carmel Pharma AB
  • Cartagenia
  • Cell Signaling Technology
  • Celldex Therapeutics
  • Cellestis Ltd.
  • Cellular Research
  • Cephalon
  • Cepheid
  • Chugai Pharmaceuticals
  • Clearbridge BioMedics
  • Constitutional Medical, Inc. (CMI)
  • Crescendo Bioscience
  • Dako
  • Danaher
  • DiaMed Holding
  • Diasis Diagnostik Sistemler Ticaret Ve Sanayi A.S.
  • DiaSorin S.p.A.
  • Diesse
  • Dionex
  • Eli Lilly
  • Epitomics
  • EQT
  • Erba Diagnostics Mannheim GmbH Group
  • Erba -Transasia
  • eScreen Inc.
  • EskoArtwork
  • European Commission (EC)
  • Fast Track Diagnostics (FTD)
  • Focus Diagnostics
  • Food and Drug Administration (FDA)
  • Furuno Electric Co., Ltd.
  • GenCell Biosystems
  • Genentech
  • Genetic Analysis
  • Genomic Health
  • Genzyme Genetics
  • GlaxoSmithKline (GSK)
  • GnuBIO Inc.
  • Grifols
  • Haliodx
  • Hologic, Inc.
  • Illumina, Inc.
  • Inostics Inc.
  • Institut Merieux
  • InterMune
  • Ipsogen S.A.
  • IRIS International
  • JEOL Ltd.
  • Johnson & Johnson
  • Kappa Biosystems, Inc.
  • Katakura Industries Co., Ltd.
  • Kem-En-Tec Diagnostics
  • Knome, Inc.
  • Koninklijke Philips N.V.
  • LabIndia
  • Laboratory Corporation of America (LabCorp)
  • Laetus
  • Leica Microsystems
  • Life Technologies
  • LipoScience, Inc.
  • Lyon Civil Hospitals
  • Maxmat SA
  • MDS
  • MDxHealth
  • Medica
  • Merck & Co.
  • Merck KGaA
  • Monogram Biosciences
  • MorphoSys AG
  • Myriad Genetics
  • Navman Wireless
  • Nobel Biocare
  • NovioGendix Holding B.V.
  • Oncomed
  • Oxford University
  • Pall
  • Pasteur Sanofi Diagnostics
  • PerkinElmer, Inc.
  • Pfizer
  • Phadia
  • Pharma Mar
  • Phenomenex
  • PreAnalytiX GmbH
  • Propel Labs
  • QIAGEN
  • Quest Diagnostics
  • Remote Diagnostic Technologies (RDT)
  • Roche
  • Rules-Based Medicine Inc.
  • Schering Plough
  • Seahorse Bioscience
  • Siemens AG
  • Siemens Healthcare GmbH
  • Siemens Healthineers
  • Sividon Diagnostics
  • St. Jude Medical
  • Sysmex
  • Sysmex Corporation
  • Sysmex Inostics GmBH
  • Thermo Fisher
  • Thermo Fisher Scientific
  • TOA Corporation
  • TOA Medical Electronics
  • Tocagen
  • Transasia Bio-Medicals Ltd.
  • Tulip Diagnostics Private Ltd.
  • Unisensor
  • Van Andel Research Institute
  • Vanadis Diagnostics, AB
  • Ventana
  • ViiV Healthcare
  • VSS Monitoring
  • XOS
  • X-Rite

The global in vitro diagnostics (IVD) market is estimated to have reached $69.2bn in 2018. The largest sector of the IVD market in 2018 was point of care diagnostics segment, generating sales of $19.4bn in 2018, which accounted for 28.0% of overall IVD sales.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 204-page report you will receive 180 charts - all unavailable elsewhere.

The 204-page report provides clear detailed insight into the leading in vitro diagnostics (IVD) companies. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

In Vitro Diagnostics (IVD) revenues in 2017 and 2018 by Class:

  • Point-of-Care
  • Clinical Chemistry
  • Immunochemistry
  • Hematology
  • Microbiology
  • Genetic Testing
  • Others

In Vitro Diagnostics (IVD) revenue forecast for 2019, 2024 and 2029 by Class:

  • Point-of-Care
  • Clinical Chemistry
  • Immunochemistry
  • Hematology
  • Microbiology
  • Genetic Testing
  • Others

This report profiles and discusses the selected leading in vitro diagnostics (IVD) companies:

  • Abbott Laboratories
  • Arkray, Inc.
  • Becton, Dickinson and Company (BD)
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Dako (Agilent Technologies)
  • Danaher Corporation
  • Genomic Health
  • Laboratory Corporation of America (LabCorp)
  • MDxHealth
  • Myriad Genetics
  • QIAGEN
  • Roche
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific
  • Other companies

This report discusses sales and recent performance analysis, key products, strengths and challenges, historical revenues, revenue forecast, market share forecast, mergers and acquisition (M&A) activity, strategic collaborations

Analysis of factors that drive and restrain the in vitro diagnostics (IVD) market.

Key Questions Answered by this Report:

  • Who are the leading IVD manufacturers?
  • What factors are driving and restraining growth for the leading IVD manufacturers?
  • How have the leading IVD manufacturers performed financially in recent years?
  • Which IVD manufacturers will experience revenue growth over the coming years?
  • What are the strength and weakness of the leading IVD manufacturers?
  • What strategies have IVD manufacturers been implementing for sales growth in recent years?

Visiongain's study is intended for anyone requiring commercial analyses for the leading in vitro diagnostics (IVD) companies. You find data, trends and predictions.

Buy our report today Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2019-2029: Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Roche, Siemens AG, Sysmex, Other Companies’.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 How This Report Delivers Information
  • 1.2 Main Questions This Report Answers
  • 1.3 Who is This Report for?
  • 1.4 Methods of Research and Analysis
  • 1.5 Frequently Asked Questions (FAQs)
  • 1.6 Associated Visiongain Reports
  • 1.7 About Visiongain

2. An Introduction to In Vitro Diagnostics

  • 2.1 The In Vitro Diagnostics Market
    • 2.1.1 The In Vitro Diagnostics Market in 2018
  • 2.2 What are In Vitro Diagnostic (IVD) Tests?
  • 2.3 Classifying In Vitro Diagnostics
    • 2.3.1 The US Classification
    • 2.3.2 The EC (European Commission) Classification
    • 2.3.3 Regulatory Issues in the IVD Market
      • 2.3.3.1 Regulation of IVD Tests
      • 2.3.3.2 Lack of Clarity Can Be Costly
  • 2.4 Types of IVD Test
    • 2.4.1 Point of Care Diagnostics
    • 2.4.2 Clinical Chemistry
    • 2.4.3 Microbiology
      • 2.4.3.1 Regulatory Differences with IVD Microbiology Tests
    • 2.4.4 Haematology
    • 2.4.5 Immunochemistry
    • 2.4.6 Genetic Testing
  • 2.5 The IVD Market: Overall Revenue Forecast to 2029
    • 2.5.1 Market Drivers, 2019-2029
    • 2.5.2 Market Restraints, 2019-2029
    • 2.5.3 Future of the IVD Industry
  • 2.6 Company Comparison
  • 2.6.1 Fragmented Market
  • 2.6.2 IVD Market: Leading Manufacturers in 2018

3. The Leading US in Vitro Diagnostic Companies, 2019-2029

  • 3.1 Danaher Corporation
    • 3.1.1 Sales and Recent Performance Analysis
    • 3.1.2 Diagnostics
    • 3.1.3 Key Products
    • 3.1.4 Danaher Manufacturing Capabilities
    • 3.1.5 Danaher IVD Segment: Strengths and Challenges
    • 3.1.6 Danaher's Life Sciences and Diagnostics Revenues
    • 3.1.7 IVD Revenue Forecast, 2018-2029
    • 3.1.8 Recent Mergers and Acquisition (M&A) Activity
  • 3.2 Abbott Laboratories
    • 3.2.1 Sales and Recent Performance Analysis
    • 3.2.2 Abbott: Diagnostics Segment
    • 3.2.2.1 In Vitro Diagnostics Products
    • 3.2.3 Abbott IVD Segment: Strengths and Challenges
    • 3.2.4 Abbott Diagnostics Historical Revenues, 2015-2017
    • 3.2.5 IVD Revenue Forecast, 2019-2029
    • 3.2.6 Recent M&A Activity and Strategic Collaborations
      • 3.2.6.1 Collaboration with GSK
      • 3.2.6.2 Collaboration with Merck
      • 3.2.6.3 Acquisition of Alere, Inc.
  • 3.3 Bio-Rad Laboratories, Inc.
    • 3.3.1 Sales and Recent Performance Analysis
    • 3.3.2 Clinical Diagnostics
      • 3.3.2.1 In Vitro Diagnostics
    • 3.3.3 IVD Revenue 2018
    • 3.3.4 IVD Revenue Forecast, 2019-2029
    • 3.3.5 Recent M&A Activity and Strategic Collaborations
    • 3.3.6 Potential Bio-Rad Labs Takeover Seen in Near-Term
  • 3.4 Becton, Dickinson and Company
    • 3.4.1 Global Presence
    • 3.4.2 Distribution
    • 3.4.3 R&D
    • 3.4.4 Sales and Recent Performance Analysis
      • 3.4.4.1 Historical Sales Performance Analysis
    • 3.4.5 BD Diagnostics Revenue
    • 3.4.6 IVD Revenue Forecast, 2019-2029
    • 3.4.7 Recent M&A Activity and Strategic Collaborations
  • 3.5 Thermo Fisher Scientific
    • 3.5.1 Historical Sales and Recent Performance Analysis
    • 3.5.2 Clinical Diagnostics
    • 3.5.3 Key Products
    • 3.5.4 Thermo Fisher's Manufacturing Capabilities
    • 3.5.5 Thermo Fisher's Diagnostics Revenues
    • 3.5.6 IVD Revenue Forecast 2019-2029
    • 3.5.7 Recent Mergers and Acquisition Activity

4. The Leading European In Vitro Diagnostic Companies, 2019-2029

  • 4.1 Hoffmann-La Roche Ltd.
    • 4.1.1 Global Presence
    • 4.1.2 Sales and Recent Performance Analysis
    • 4.1.3 Roche Diagnostics
    • 4.1.4 R&D Capabilities
    • 4.1.5 Growing Portfolio of Diagnostic Products
      • 4.1.5.1 Exploring Strategies in the Neurological Sector
    • 4.1.6 IVD Revenue Forecast 2019-2029
    • 4.1.7 Recent M&A Activity and Strategic Collaborations
  • 4.2 Siemens AG
    • 4.2.1 Sales and Recent Performance, 2017
    • 4.2.2 Siemens Healthcare
      • 4.2.2.1 Siemens Diagnostics
      • 4.2.2.2 Outperforming the Market
      • 4.2.2.3 In Vitro Diagnostics
    • 4.2.3 IVD Revenue Forecast 2019-2029
    • 4.2.4 Recent M&A Activity and Strategic Collaborations
      • 4.2.4.1 Partnership with ViiV Healthcare
      • 4.2.4.2 Partnership with Tocagen
      • 4.2.4.3 Acquisition of Fast Track Diagnostics
  • 4.3 bioMérieux S.A.
    • 4.3.1 Sales and Recent Performance, 2017
    • 4.3.2 IVD Revenue Forecast 2019-2029
    • 4.3.3 Recent M&A Activity and Strategic Collaborations
      • 4.3.3.1 Partnership with GSK
      • 4.3.3.2 Partnership with Ipsen
      • 4.3.3.3 Partnership with Institute Merieux and Institute Pasteur
      • 4.3.3.4 Collaboration with Hospices Civils de Lyon
      • 4.3.3.5 Acquisition of ARGENE
      • 4.3.3.6 Equity Interest in Knome

5. The Leading Japanese In Vitro Diagnostic Companies, 2019-2029

  • 5.1 Sysmex Corporation
    • 5.1.1 Global Presence and Distribution
    • 5.1.2 Sales and Recent Performance Analysis
    • 5.1.3 Sysmex Diagnostics
    • 5.1.4 IVD Revenue Forecast 2019-2029
    • 5.1.5 Recent M&A Activity and Strategic Collaborations
      • 5.1.5.1 Acquisition of Katakura's Research Institute of Biological Science
      • 5.1.5.2 Collaboration with IDEXX Labs to Expand into Animal Diagnostics
  • 5.2 Arkray, Inc.
    • 5.2.1 Global Presence
    • 5.2.2 R&D
    • 5.2.3 IVD Product Portfolio
    • 5.2.4 Sales and Recent Performance Analysis
    • 5.2.5 IVD Revenue Forecast 2019-2029

6. Emerging In Vitro Diagnostic Companies, 2018

  • 6.1 Pipeline and Other Companies: An Overview, 2018
  • 6.2 Other Prominent In Vitro Diagnostic Players
  • 6.3 Dako (Agilent Technologies)
    • 6.3.1 Sales and Recent Performance Analysis
    • 6.3.2 M&A Activity and Other Key Developments
  • 6.4 Genomic Health, Inc.
    • 6.4.1 Sales and Recent Performance Analysis
    • 6.4.2 R&D Capabilities
      • 6.4.2.1 TAILORx Clinical Trial
      • 6.4.2.2 RxPonder Trial
      • 6.4.2.3 Partnership with Oncomed
  • 6.5 Laboratory Corporation of America (LabCorp)
    • 6.5.1 Sales and Recent Performance Analysis
    • 6.5.2 In Vitro Diagnostics
  • 6.6 Recent M&A Activity and Other Key Developments
    • 6.6.1 Non-Exclusive License Agreement with Merck
    • 6.6.2 Acquisition of Genzyme Genetics
    • 6.6.3 Partnership with ARCA Biopharma
  • 6.7 MDxHealth, Inc.
    • 6.7.1 Sales and Recent Performance Analysis, 2017
    • 6.7.2 R&D Capabilities
    • 6.7.3 In Vitro Diagnostics
      • 6.7.3.1 PharmacoMDx
      • 6.7.3.2 PredictMDx for Brain Cancer
      • 6.7.3.3 PredictMDx for Colon Cancer
      • 6.7.3.4 Partnership with GSK
  • 6.8 Myriad Genetics, Inc.
    • 6.8.1 Sales and Recent Performance Analysis
    • 6.8.2 R&D Capabilities
    • 6.8.3 In Vitro Diagnostics
  • 6.8.3.1 Myriad RBM
    • 6.8.4 M&A Activity and Recent Partnerships
      • 6.8.4.1 Agreement with BioMarin Pharmaceutical
      • 6.8.4.2 Acquisition of Myriad RBM
      • 6.8.4.3 Strategic Debt Investment in Crescendo Bioscience
      • 6.8.4.4 Agreement with Cephalon
      • 6.8.4.5 Agreement with PharmaMar
  • 6.9 QIAGEN N.V.
    • 6.9.1 Sales and Recent Performance Analysis
    • 6.9.2 Continued Expansion in the Emerging Markets
    • 6.9.3 R&D Capabilities
      • 6.9.3.1 More than 15 Projects to Co-Develop and Market Diagnostic Products
      • 6.9.3.2 Provider of Choice for Molecular Diagnostic Tools
    • 6.9.4 Recent M&A Activity and Other Developments
      • 6.9.4.1 Acquisition of Cellestis Ltd.
      • 6.9.4.2 Acquisition of Ipsogen
      • 6.9.4.3 Partnership with Pfizer
      • 6.9.4.4 Partnership with Eli Lilly

7. Other In-Vitro Diagnostic Companies, 2018

  • 7.1 Hologic, Inc.
    • 7.1.1 Sales and Recent Performance Analysis
    • 7.1.2 In Vitro Diagnostics
    • 7.1.3 Recent M&A Activity and Strategic Collaborations
  • 7.2 Bayer AG
    • 7.2.1 Sales and Recent Performance Analysis
    • 7.2.2 In Vitro Diagnostics
    • 7.2.3 Recent M&A Activity and Strategic Collaborations
  • 7.3 Transasia Bio-Medicals Ltd.
    • 7.3.1 In Vitro Diagnostics
    • 7.3.2 Recent M&A Activity and Strategic Collaborations
  • 7.4 PerkinElmer, Inc.
    • 7.4.1 Sales and Recent Performance Analysis
    • 7.4.2 In Vitro Diagnostics
    • 7.4.3 Recent M&A Activity and Strategic Collaborations
  • 7.5 DiaSorin S.p.A.
    • 7.5.1 Sales and Recent Performance Analysis
    • 7.5.2 In Vitro Diagnostics
    • 7.5.3 Recent M&A Activity and Strategic Collaborations
  • 7.6 Koninklijke Philips N.V.
    • 7.6.1 Sales and Recent Performance Analysis
    • 7.6.2 In Vitro Diagnostics
    • 7.6.3 Recent M&A Activity and Strategic Collaborations
  • 7.7 Illumina, Inc.
    • 7.7.1 Sales and Recent Performance Analysis
    • 7.7.2 In Vitro Diagnostics
    • 7.7.3 Recent M&A Activity and Strategic Collaborations
  • 7.8 Kem-en-tec Diagnostics A/S
    • 7.8.1 In Vitro Diagnostics
    • 7.8.2 Recent M&A Activity and Strategic Collaborations

8. Conclusions

  • 8.1 In Vitro Diagnostics: Attractive Segment of the Healthcare Market
  • 8.2 Big Pharma Dominated the IVD Market in 2018
  • 8.3 The Rise of ‘Generic Medical Devices'
  • 8.4 What Will Succeed in the IVD Market?
  • 8.5 Small Companies Can Have a Big Impact on the Industry and Market to 2029

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form
Back to Top
전화 문의
F A Q